Array Biopharma (ARRY) Reports Data Presentation On ARRY-797 at ESC Congress

August 19, 2016 3:28 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Array BioPharma Inc. (NASDAQ: ARRY) today announced that results from a Phase 2 study of ARRY-797 will be presented at the 2016 European Society of Cardiology (ESC) Congress, which will be held August 27 – 31, 2016 in Rome, Italy.



Phase 2 study of A797, an oral, selective p38 mitogen-activated protein kinase inhibitor, in patients with lamin A/C-related dilated cardiomyopathy (Abstract #P4981)


Calum A. MacRae, MD


Tuesday, August 30, 10:19 a.m. CEST

Updated and additional data will be provided at the conference beyond what is included in the abstract.

All abstracts can be accessed through the ESC website, or on this web page:

The ARRY-797 abstract can be found by clicking this LINK.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment